SITRYX THERAPEUTICS
Sitryx is a biopharmaceutical company focused on regulating cell metabolism to develop first-in-class disease modifying therapeutics in immuno-oncology and immuno-inflammation. The company was co-founded by a team of world-leading scientists from the United States and Europe who have contributed significantly to the field of immunometabolism. Sitryx was founded in 2018 with seed funding from SV Health Investors and raised $30 million Series A funding from an international syndicate of specialist investors including SV Health Investors, Sofinnova Partners, Longwood Fund and GSK. The company has a pipeline of projects at multiple stages of drug discovery. Sitryx is headquartered in Oxford, UK.
SITRYX THERAPEUTICS
Social Links:
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2018-10-01
Address:
Oxford, Oxfordshire, United Kingdom
Country:
United Kingdom
Website Url:
http://www.sitryx.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
40 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Google Tag Manager Google Universal Analytics Global Site Tag Mobile Non Scaleable Content
Similar Organizations
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Emmaus Medical
Emmaus Medical is a pharmaceutical company developing new treatments for rare diseases and conditions.
Immutep
Immutep is a biopharmaceutical company developing immunotherapeutics in oncology.
IVERIC bio
IVERIC bio is a biopharmaceutical company developing novel therapies for age-related macular degeneration.
PIQUR Therapeutics
PIQUR Therapeutics is a Swiss pharmaceutical company focusing on the discovery and development of anti-cancer drugs.
Current Advisors List
Current Employees Featured
Founder
Investors List
Eli Lilly
Eli Lilly investment in Corporate Round - Sitryx Therapeutics
GSK
GSK investment in Series A - Sitryx Therapeutics
SV Health Investors
SV Health Investors investment in Series A - Sitryx Therapeutics
Sofinnova Partners
Sofinnova Partners investment in Series A - Sitryx Therapeutics
Longwood Fund
Longwood Fund investment in Series A - Sitryx Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2022-04-12 | Sitryx Therapeutics Strengthens Leadership Team With Appointment of Ravi M. Rao as Chief Medical Officer |
Official Site Inspections
http://www.sitryx.com Semrush global rank: 6.87 M Semrush visits lastest month: 723
- Host name: 76.76.21.21
- IP address: 76.76.21.21
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Sitryx Therapeutics"
About - Sitryx
Fiona IrvineVice President of People and Organization. ... Sitryx was founded by six world leading researchers in the field of immunometabolism, immunology and immunoregulation with the …See details»
Pioneers in immunometabolism - Sitryx
Read More → Sitryx initiates Phase 1 clinical trial of potential disease-modifying treatment for atopic dermatitis SYX-521920th March 2025 Sitryx announces leadership transition2nd July 2024 Sitryx nominates SYX-5219 a novel, oral …See details»
Sitryx Therapeutics - Crunchbase Company Profile
Sitryx is a biopharmaceutical company focused on regulating cell metabolism to develop first-in-class disease modifying therapeutics in immuno-oncology and …See details»
Sitryx announces leadership transition
Jul 2, 2024 Sitryx founding Board member and Managing Partner at SV Health Investors, Kate Bingham commented: “We have been huge supporters of both the world class science and …See details»
Sitryx 2025 Company Profile: Valuation, Funding
When was Sitryx founded? Sitryx was founded in 2016. Where is Sitryx headquartered? Sitryx is headquartered in Oxford, United Kingdom. What is …See details»
Sitryx Therapeutics - Funding, Financials, Valuation & Investors
Sitryx is a biopharmaceutical company develops disease modifying therapeutics in immuno-oncology and immuno-inflammation. New. Resources. Advanced Search. ... How much …See details»
Sitryx announces leadership transition - SV Health Investors
Oxford, UK – 2 July 2024 – Sitryx Therapeutics (“the Company”), a biopharmaceutical company focused on modulating immune cell metabolism to advance a new generation of therapies for …See details»
Sitryx Therapeutics - Contacts, Employees, Board Members
Sitryx is a biopharmaceutical company develops disease modifying therapeutics in immuno-oncology and immuno-inflammation. ... Experience the new Crunchbase, powered by AI . …See details»
Sitryx - VentureRadar
Lilly will make a $10 million equity investment in Sitryx as part of licensing and research collaboration. Source: prnewswire.com. Venture-funding News. Equity Funding. 09 Oct 2018. …See details»
Immunometabolism company Sitryx expands into new space at …
Mar 8, 2021 Sitryx is a biopharmaceutical company focused on regulating cell metabolism to develop disease-modifying therapeutics in immuno-oncology and immuno-inflammation. …See details»
Sitryx - Employees, Org Chart, News, Posts, Hirings on Mar 2025
Sitryx is a biopharmaceutical company focused on regulating cell metabolism to develop first-in-class disease modifying therapeutics in immuno-oncology and immuno-inflammation. The …See details»
Sitryx Company Profile - Office Locations, Competitors, Revenue
Sitryx has 5 employees across 2 locations and $30 m in total funding,. See insights on Sitryx including office locations, competitors, revenue, financials, executives, subsidiaries and more …See details»
Fiona Irvine - Sitryx
Vice President of People and Organization. Fiona joined Sitryx as Head of People & Culture in September 2022. She has 25 years of HR experience working across a range of industries …See details»
GlaxoSmithKline helps immunometabolism startup Sitryx to $30M …
Oct 8, 2018 “Sitryx presented an opportunity for me to build on my pharmaceutical experiences, to lead an organization and work with an excellent set of founding scientists,” Weir said. …See details»
Sitryx - Overview, News & Similar companies | ZoomInfo.com
Mar 4, 2024 Sitryx's proprietary science is led by a highly experienced management team and supported by world class academic founders. Sitryx was founded by six world-leading …See details»
Sitryx - Biotech Careers
Sitryx is a biopharmaceutical company focused on regulating cell metabolism to develop first-in-class disease modifying therapeutics in immuno-oncology and immuno-inflammation. They …See details»
The Science - Sitryx
Sitryx is building a broad pipeline of first- and best-in-class therapies by identifying novel targeted approaches based on how changes in metabolism modulate immune cell function. Intervening …See details»
Sitryx signs potential $880m drug development deal
Apr 1, 2020 Furthermore, Sitryx may receive development milestones of up to $820m, commercialisation milestones and royalties on future sales. Sitryx CEO Neil Weir said: “We …See details»
Sitryx announces collaboration partner Lilly has commenced a …
Jan 4, 2024 In 2020, Sitryx formed an exclusive global licensing and research collaboration with Eli Lilly and Company. The Company has a pipeline of projects at multiple stages of drug …See details»
Pipeline - Sitryx
Sitryx’s SIT-052 is a GLS1 inhibitor taken via an inhaled approach for the induction of the selective breakdown of senescent cells which contribute too ongoing fibrosis and inflammation …See details»